Tìm theo
Tetrathiomolybdate
Các tên gọi khác (1) :
  • ATN-224
enzyme inhibitors, angiogenesis inhibitors, chelating agents
Thuốc Gốc
Small Molecule
CAS: 16330-92-0
CTHH: H2MoS4
PTK: 226.22
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
H2MoS4
Phân tử khối
226.22
Monoisotopic mass
227.80934067
InChI
InChI=1S/Mo.2H2S.2S/h;2*1H2;;/p-2
InChI Key
InChIKey=VVRHUOPINLMZBL-UHFFFAOYSA-L
IUPAC Name
disulfanylidenemolybdenum disulfanide
Traditional IUPAC Name
molybdenum disulfide dihydrosulfide
SMILES
[SH-].[SH-].S=[Mo]=S
Độ tan chảy
300 °C with decomposition
logP
0.77
Refractivity
18.87 m3·mol-1
Polarizability
8.57 Å3
Polar Surface Area (PSA)
0
Rotatable Bond Count
0
H Bond Acceptor Count
0
H Bond Donor Count
0
Physiological Charge
0
Number of Rings
0
Bioavailability
1
Rule of Five
true
Dược Lực Học : Tetrathiomolybdate demonstrated the ability to reduce toxic free copper levels and substantially improve clinical neurologic outcomes in Wilson’s patients. Studies also showed it is capable of specifically inhibiting chronic fibrotic disease processes in the lung.
Cơ Chế Tác Dụng : Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body. Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF).
Chỉ Định : Investigated for use/treatment in liver disease and pulmonary fibrosis.
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Copexa
  • Công ty :
    Sản phẩm biệt dược : Coprexa
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05088
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5245480
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=7807218
ChemSpider
http://www.chemspider.com/Chemical-Structure.4413909.html
Wikipedia
http://en.wikipedia.org/wiki/Tetrathiomolybdate
... loading
... loading